Skip to content
Peptidepedia

PT-141 (Bremelanotide) Dosage Guide: Protocols, Timing & How Much to Take (2026)

From Peptidepedia, the trusted peptide wiki.

Dosage Protocols

FDA-Approved Dosing (Vyleesi):

  • 1.75 mg subcutaneously, administered at least 45 minutes before anticipated sexual activity
  • Maximum one dose per 24-hour period
  • Maximum 8 doses per month
  • Patients should determine their optimal timing based on personal experience with onset and duration of effects

Off-Label Dosing Considerations:

Off-label use in men typically follows the same 1.75 mg subcutaneous dose, though some clinicians adjust within a range of 1 to 2 mg based on individual response and tolerability. Lower starting doses (0.5 to 1 mg) may be considered for first-time users to assess tolerance, particularly regarding nausea. Anti-nausea medication such as ondansetron taken 30 minutes before PT-141 can reduce gastrointestinal side effects.

The monthly frequency limit of 8 doses is based on the prescribing information and reflects the on-demand nature of the drug. PT-141 is not intended for daily use, and dose frequency should be kept to the minimum effective amount.

Frequently Asked Questions

Nausea is the most common side effect, affecting approximately 40% of patients and most pronounced with the first dose. Other common side effects include flushing (20%), injection site reactions (13%), and headache (11%). PT-141 also causes a transient rise in blood pressure and reduction in heart rate.

PT-141 reaches peak plasma concentration within 30 to 60 minutes of subcutaneous injection. Most users experience onset of effects within 45 minutes, with maximal therapeutic benefit occurring 2 to 4 hours post-dose. Effects may persist for 6 to 8 hours.

The FDA-approved dose of Vyleesi is 1.75 mg administered subcutaneously at least 45 minutes before anticipated sexual activity. No more than one dose should be taken within a 24-hour period, and use should not exceed 8 doses per month.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908.
  2. Clayton AH, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-917.
  3. Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-38.
  4. Safarinejad MR. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008;179(3):1066-71.
  5. Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.
  6. Simon JA, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022;27(1):61-68.
  7. U.S. Food and Drug Administration. Vyleesi (bremelanotide injection) prescribing information. NDA 210557. 2019.
  8. Dhillon S. Bremelanotide: first approval. Drugs. 2019;79(14):1599-1606.
  9. Palatin Technologies. FDA approves new drug application for Vyleesi (bremelanotide injection). Press release. June 21, 2019.
  10. World Anti-Doping Agency. The 2026 Prohibited List. WADA.
←Read the full PT-141 (Bremelanotide) guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”